{"filing":{"accession_number":"0001437749-26-029242","cik":"0001131343","ticker":"PRNAF","company_name":"ALTERITY THERAPEUTICS LTD","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"athe20260831_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131343/000143774926029242/athe20260831_6k.htm"},"events":[{"id":30452,"run_id":27910,"accession_number":"0001437749-26-029242","anchor_item_number":"EX-99.1","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Alterity Therapeutics entered into an underwriting agreement with MST Financial Services to underwrite the exercise of up to 8,400,000 listed options, expected to raise approximately A$4.2 million minimum (up to A$7.96 million maximum). While technically an equity issuance rather than debt, this represents a material capital-raising transaction that creates new direct financial obligations and dilutes existing shareholders. The underwriting structure and the company's stated use of proceeds (late-stage clinical development and working capital) make this a material financing event comparable to a debt or equity issuance under Item 2.03 / 3.02 frameworks.","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33050,"accession_number":"0001437749-26-029242","item_number":"EX-99.1","item_title":"ex_1010753.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Alterity Therapeutics entered into an underwriting agreement with MST Financial Services to underwrite the exercise of up to 8,400,000 listed options, expected to raise approximately A$4.2 million minimum (up to A$7.96 million maximum). While technically an equity issuance rather than debt, this represents a material capital-raising transaction that creates new direct financial obligations and dilutes existing shareholders. The underwriting structure and the company's stated use of proceeds (late-stage clinical development and working capital) make this a material financing event comparable to a debt or equity issuance under Item 2.03 / 3.02 frameworks.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:36.662087+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33050,"accession_number":"0001437749-26-029242","item_number":"EX-99.1","item_title":"ex_1010753.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Alterity Therapeutics entered into an underwriting agreement with MST Financial Services to underwrite the exercise of up to 8,400,000 listed options, expected to raise approximately A$4.2 million minimum (up to A$7.96 million maximum). While technically an equity issuance rather than debt, this represents a material capital-raising transaction that creates new direct financial obligations and dilutes existing shareholders. The underwriting structure and the company's stated use of proceeds (late-stage clinical development and working capital) make this a material financing event comparable to a debt or equity issuance under Item 2.03 / 3.02 frameworks.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:36.662087+00:00","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-08-31"}]}